Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP4C | P60510 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | XPO1 | O14980 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10731783 | 0.91 | PPP4C (0.75) | PPP4CMAPTTDP1MEN1JAK2 | |
| SCHEMBL10731774 | 0.91 | PPP4C (0.75) | PPP4CMAPTTDP1MEN1JAK2 | |
| SCHEMBL442794 | 0.91 | PPP4C (0.75) | PPP4CMAPTTDP1MEN1JAK2 | |
| Phosphoric Acid SCHEMBL31628217 | 0.86 | PPP4C (0.76) | PPP4CMAPTTDP1MEN1JAK2 | |
| SCHEMBL442224 | 0.86 | PPP4C (0.77) | PPP4CMAPTTDP1MEN1JAK2 | |
| SCHEMBL442761 | 0.86 | PPP4C (0.67) | PPP4CMAPTTDP1MEN1JAK2 | |
| Fostriecin SCHEMBL10738892 | 0.85 | PPP4C (1.00) | PPP4CMAPTTDP1MEN1JAK2 | |
| Fostriecin SCHEMBL469219 | 0.85 | PPP4C (1.00) | PPP4CMAPTTDP1MEN1JAK2 | |
| SCHEMBL444582 | 0.85 | PPP4C (0.66) | PPP4CMAPTTDP1MEN1JAK2 | |
| Fostriecin SCHEMBL10738899 | 0.85 | PPP4C (1.00) | PPP4CMAPTTDP1MEN1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623912-B2 | Fostriecin derivatives and the pharmaceutical uses thereof | BEIJING BIOSTAR TECHNOLOGIES, LTD. (CN) | 2014-01-07 | — | — | US | disclosed |
| US-20120065171-A1 | FOSTRIECIN DERIVATIVES AND THE PHARMACEUTICAL USES THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065171-A1 | FOSTRIECIN DERIVATIVES AND THE PHARMACEUTICAL USES THEREOF | FOS, FOSB, VIP | PPP4C 1459/4885MAPT 4115/4885TDP1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.